Huijing Wu

机构：Tangshan People's Hospital

发表论文 51 篇 · 总被引 509 次 · h-index 10

代表论文

• p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP (2023 · Cell Reports · 被引 39)
• Prognostic Value of Sarcopenia in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A Systematic Review and Meta-Analysis (2022 · Frontiers in Nutrition · 被引 38)
• Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma (2024 · Signal Transduction and Targeted Therapy · 被引 11)
• Value of CT spectral imaging in the differential diagnosis of sarcoidosis and Hodgkin’s lymphoma based on mediastinal enlarged lymph node: A STARD compliant article (2022 · Medicine · 被引 10)
• A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas (2023 · Blood · 被引 7)
• Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma (2024 · Leukemia · 被引 6)